Tuesday, June 2, 2009

Harvard Med School, Jack Connors, and the Manipulation of Power

Sunday’s Boston Globe reported yet another conflict of interest problem in medicine. This one, however, is on a scale that will astonish even the most jaded observers of recent events.

According to two-time Pulitzer Prize winning journalist Steve Kurkjian, Jack Connors, the chairman of the board of Partners Healthcare, never bothered to inform the board that he was the major owner of a drug industry funded CME empire. The company, M/C Communications, runs the lucrative Pri-Med courses, a series of industry-funded symposia that reach 35,000 doctors per year.

According to the article, Connors bought the company (with an investment group) for $13 million in 2000, and sold it for a whopping $450 million in 2004, personally making $250 million in profit from the deal.

So what? Jack Connors is a successful businessman and entrepreneur. There’s nothing wrong with flipping a company and making a tidy sum in the process, right?

Generally speaking, that’s true. In this case, however, there was a web of undisclosed relationships that enabled Connors to make that kind of money. Connors is neither a physician nor an educator. But he knows advertising, having co-founded Hill Holiday,
the main advertising firm for Partners. The way advertisers become rich is by finding rich companies and promising them a lucrative market for their products. In the world of industry-funded CME (which is merely a deceptive form of promoting industry products), that lucrative market consists of doctors. The more doctors you can attract to your courses, the more you can charge the drug companies that fund those courses. The best way to attract doctors is to promise them gold-plated medical education, and nowhere does this gold shine more brightly than at Harvard Medical School.

By being chairman of the board at Partners, Connors had access to the key decision makers at Harvard Medical School, access that would have easily allowed him to negotiate deals on behalf of his company, M/C Communications. According to the Globe article, M/C has an “exclusive commercial relationship” with Harvard Medical School. The Pri-Med website is quick to make drug companies aware of this fact:


“Because of our relationship with Harvard Medical School, clinicians are drawn to our conferences and the opportunity to engage with peers and learn about the latest advancements in the medical community.”

Did Connors actually exploit his position with Partners to hawk medicine’s equivalent of Boardwalk and Park Place to drug companies? He denies it, saying that he was only a “passive investor” and that he never spoke to Harvard’s dean about his company. Maybe he is telling the truth here...but then again, maybe not. Connors certainly damages his own credibility when he defends his decision not to disclose his ownership of M/C Communications to the Board:

“Connors said he was under no obligation to disclose his ownership of M/C Communications to the Partners board. He said that while there is an "affiliation" between Harvard Medical School and the two Partners hospitals, there is no formal contract between them.”

This is like saying that when two people marry there is not really a contract between them, only an “affiliation.”

Apparently, Connors has studied the Bill Clinton playbook of wordsmithing . Partners was literally founded in 1994 by Harvard’s two main teaching hospitals, Mass General and Brigham and Womens.
There may be no “formal contract” between Partners and Harvard, but without the Partners hospitals, Harvard Medical School would have all the power, money, and prestige of a local community college.

Former Partner’s board members interviewed by Kurkjian were dismayed to learn about Connors’ odd opinion about appropriate disclosure—unfortunately, they opted to remain anonymous, perhaps fearing repercussions from Connors.

W. Micheal Hoffman, who is a specialist in corporate conflict of interest policies, explained to the Globe why this is a major PR problem for Partners:


"That's not good governance," said Hoffman, noting that M/C's relationships with Harvard Medical School and the pharmaceutical industry were close enough that Partners trustees should have discussed it. He said the board could have placed restrictions on Connors's private ventures or even demanded that he choose between his for-profit enterprises and his nonprofit chairmanship. Or, he said, after vetting the issue, the board could have decided to take no action.
"People are going to think that the trustees have either a laissez-faire or old-boy network attitude toward conflicts of interest," Hoffman said. "And Partners can only lose with that attitude out there."


All in all, this is a remarkable--if nauseating--example of the manipulation of power at the highest level of American medicine. Kudos to Kurkjian and the Globe for printing it. This is the kind of investigative journalism that we will lose if our newspapers go under—so keep up your subscriptions!

Wednesday, May 27, 2009

ACCME's Good Courses, Bad Courses--Mystery Solved?

According to an anonymous source, ACCME’s newly proposed “Commercial Support Free CME” did not arise directly from ACCME. Rather, the idea was hatched in response to pressure from the American Board of Medical Specialties, which apparently takes a very dim view of industry-supported CME.

Here’s the background of this increasingly complicated issue.

As I wrote in a prior post, the ACCME has floated the concept of distinguishing two different types of CMEs—a Commercial Support Free CME versus the standard "anything goes" industry-funded CME (see this report
from their March 2009 Board meeting for the details.) This has struck many as a strange idea: the national certifying body presents a refined definition of superior vs. inferior education, but at the same time declares that they would happily accredit inferior education anyway.

The plot got even murkier after the American Medical Association’s Council on Ethical and Judicial Affairs (CEJA) recently released its second effort at defining the ethics of industry funding of medical education. In their first report,
which was released last year, the committee proclaimed that companies should not pay for doctor’s education when those same companies stand to benefit financially from the content of the education. While that made eminently good sense, it angered a subculture of doctors who prefer not to pay for their own education, so the proposal was tabled, and the committee was directed to come up with a more palatable version of medical ethics, which they recently released. This document, like ACCME’s proposal, proposes the same surreal notion of two CMEs: one that is “ethically preferrable” (involving no commercial support) and another that is only “ethically permissable” (funded by drug companies).

Essentially, the world’s premier medical organization is saying that while we should strive for the best ethics, dodgy ethics are also acceptable—at least when a lot of money is at stake.

Well, I finally solved the mystery of the two CMEs. At the heart of this case is neither the ACCME nor the AMA, but rather the American Board of Medical Specialties (ABMS). The ABMS sets the standards for maintenance of specialty board certification. Depending on your specialty, you have to undergo an exam or other evaluation process every few years so that you can continue to call yourself a “Board-Certified” psychiatrist, cardiologist, dermatologist, and so on. Apparently, the ABMS, realizing that industry-funded CME is quickly losing the public's trust, would prefer to no longer allow doctors to submit commercial CME as part of their requirements. But in order to be able to distinguish commercial CME from non-commercial CME, ABMS needed help from the organization that accredits CME, namely, the ACCME. So they asked the ACCME to create a separate Commercial-Free CME designation. ACCME complied, and the result is the proposal and call for comments posted on their website.

I called ABMS to verify they they are the force behind ACCME's proposal, but I was told that this was a "misunderstanding." I then went to my source, who said that ABMS is backtracking because of angry comments from medical societies. Finally, I contacted ACCME to find out if the Commercial Free CME designation was, in fact, prompted by ABMS, and I am still awaiting their response.

Does any of this really matter? Who cares who came up with the idea, or who pressured whom? It matters because we all deserve to know exactly where our major medical organizations stand on issues that are crucial to the public health. And the education of physicians is one of the most crucial issues of all.

Wednesday, May 20, 2009

Med Page Today Interviews Dr. Paul Appelbaum and Me on Industry Relationships


Yesterday, John Gever of Med Page Today interviewed me and Dr. Paul Appelbaum on various topics about the relationship between the pharmaceutical industry and psychiatry, which I have posted above for your viewing pleasure. Dr. Appelbaum is a former president of the APA and is the chairman of the "Ad Hoc Work Group on Relationships Between Psychiatrists and Medical Industries." He and the members of this group have drafted a report with recommendations for how we can clean up our act. While the report has not yet been formally approved by the Board of Trustees and is therefore not public, I can tell you that it contains many of the same elements as the recent Institute of Medicine report, which I described here. Appelbaum's report was discussed in the APA Assembly on Sunday and the review was frankly somewhat mixed. What will happen next is that the Board of Trustees will continue to elicit feedback from the APA membership and will eventually vote on whether to adopt some version of the current report. My prediction is that the current version will be adopted with very few changes, but that's only a prediction (I'm not a member of the Board, just the Assembly).

There have been a number of excellent symposia over the last few days on how to set the right distance between doctors and commercial interests and I'm coming away from this meeting with high optimism that we are really turning a corner in our profession.

Monday, May 18, 2009

Dispatch from the APA Annual Meeting: The "Product Theater"

I'm writing this from the Press Room in the Moscone Convention Center in San Francisco, where the annual meeting of the American Psychiatric Association is being held. On my schedule this morning was a lecture on genetics in psychiatry by Kenneth Kendler, but once I got there a line was snaking its way into the hallway and I was out of luck. So I decided to go to one of Shire's product theaters.

You may recall that recently the APA voted to phase out industry-sponsored symposia (ISS), but they are now allowing companies to hold promotional educational events called product theaters. This one was entitled "Current Perspectives on Diagnostic and Treatment Challenges of ADHD in Adults," and was presented by Robert Lasser, who is Shire's Senior Director of Global Medical Affairs. That's him in the photo.

Overall, he made a fairly balanced pitch for diagnosing more ADHD in adults and for using Vyvanse. He is a psychiatrist, and knew his stuff. It was definitely a soft sell, compared to the experience of being visited by a Shire drug rep.

We heard the usual information (not inaccurate) about 4% of adults having ADHD, about estimates that up to 20% of patients with depression have ADHD. We heard about the ways that ADHD symptoms manifest in adults, like workaholism, possibly due to job inefficiency, frequent changes of life partners, finishing other people's sentences, low frustration tolerance, etc.... Of course, all of these are non-specific symptoms and can be seen in a huge range of other diagnoses and even in people with no psychiatric problems at all, which was something that was not mentioned. On the other hand, would this have been mentioned by a conventional key opinion leader speaking at an ISS? Probably not.

The one thing that bothered me is that, unlike at any of the other symposia, refreshments were served, consisting of a table with coffee, bagels, and muffins. Nothing extravagant, but I can assure you that there was a long line of people feeding themselves, and that this drew people in. It was not as crowded as Kendler's lecture, but then again Kendler is a world famous psychiatrist lecturing on a topic that we hear a lot less about than ADHD.

Thus far, I would say that the product theaters are a success, in that they are transparently promotional and provide a reasonable forum for us to interact at a high level with industry. I'm willing to bet that in New Orleans, they will not be allowed to provide food, because this places them in a privileged position in relation to the other events.

That's all for now--I'll be posting frequently throughout the meeting!

Thursday, May 14, 2009

Akathisia-gate Scandal in Wall Street Journal

Akathisia-gate, Bristol-Myers Squibb's ongoing efforts to distract attention from the major side effect of its blockbuster antipsychotic drug Abilify, has expanded into a scandal that was covered on the front page of today's Wall Street Journal.

Staff writer Shirley Wang profiles Andy Behrman, a man with bipolar disorder who gained notoriety when he published the book Electroboy: A Memoir of Mania. According to the article, representatives of BMS approached Behrman after the book's publication and asked him to do promotional speeches for Abilify, which was about to gain FDA approval for the treatment of mania. He initially signed a contract for $40,000, and eventually made up to $10,000/day.

The problem is, soon after he started taking Abilify, Behrman noticed restless sensations in his legs--akathisia. He said he told his BMS handlers about the side effect, which the company denies. At any rate, apparently the money he was receiving was just too good for him to tell the truth about his side effects, and he continued providing glowing endorsements. He said that the company provided him with talking points, and instructed him to reiterate in his talks that Abilify had no side effects and to avoid mentioning that he was being paid by BMS.

Of course, the company denies any malfeasance, claiming that Behrman requested an exhorbitant $7.5 million for further talks, and that the company refused the offer. The implication is that Behrman is simply a disgruntled former hired gun. We may never know the entire truth of the matter.
But knowing the sordid history of pharmaceutical marketing tactics, I'm giving Behrman the benefit of the doubt here.

Tuesday, May 12, 2009

The Next Phase in Industry-Funded Medical Education

For those who are shedding tears over the imminent demise of direct industry-funded CME, there is hope. The American Psychiatric Association will allow companies to host "product theaters" at the upcoming annual meeting in San Francisco. I just received the following invitation from Shire. As you can see, the faculty members are Shire employees, and the postcard makes it clear that "this is a promotional event. CME credit will not be available for this session." It's transparent, it's promotional education, and it's honest. I look forward to learning more about their current and upcoming products.




Abilify and the Great Akathisia Cover-up, Part 2

Yesterday, I described a patient who experienced transient severe jitteriness and shakiness on Abilify 5 mg/day. She did not want to discontinue it yet, and as I mentioned, I'll provide an update when I see her next.

Today, I saw a woman in her 30s who has suffered recurrent depression and anxiety for years. I had recently added Wellbutrin SR to her Effexor XR and Klonopin. This seemed to help decrease her crying jags initially, but after a few months she became depressed and hopeless again. She was seeing her therapist regularly, but that wasn't doing the trick. So at her last visit in March, I had her discontinue the Wellbutrin and I added Abilify at 10 mg a day. Today, she said that she stopped the Abilify after 2 weeks, because "I felt like I was having 10 cups of coffee per day." She couldn't sleep, despite taking Ambien 10 mg at night.

Nonetheless, she feels less depressed today because over the couple of months since she stopped the Abilify, she began seeing her therapist more often, up to twice a week. She feels she has more perspective on some of her stressors (an ill father, financial difficulties).


She's doing okay, but this is another case in which the much vaunted Abilify fails as a augmentation for depression, and reveals its true colors as the antipsychotic most likely to cause akathisia. Clearly, starting her at 10 mg was a mistake, and when I use it in the future, I will start at the lowest possible dose, which is 2 mg.

Meanwhile, BMS is funding plenty of CME about using antipsychotics in depression and is making sure to contract with education companies that will hire key opinion leaders who can be depended upon to go easy on Abilify's side effects. For example, here is how Abilify's side effects are discussed by a noted academic in this online symposium created by CME, LLC:

"Adverse event dropouts; you always want to know, How well were these drugs tolerated? And in this first study it was pretty darned good. I mean, it looked very placebo-like in terms of ability to stay on the drug. The data for both studies when they’re put together in the package insert have a dropout rate of about 6% for aripiprazole. So it’s a bit higher than placebo. A lot of restlessness, a lot of akathisia, you know, people sort of a little bit unable to sort of stay still, but they could tolerate the drug. That’s 23%, 25% in the package insert. So some side effects, but overall pretty good tolerability."

Hmmm...."sort of a little bit unable to sort of stay still, but they could tolerate the drug." This is the beauty of industry-funded CME. You're not buying outright deception and therefore a public relations disaster, but you are buying someone who will handle your product's liabilities with kid gloves.